Evidence map›Paper›PMID 32271155›Full record

ArticleJMIR research protocols2020

Reducing Salt Intake in China with "Action on Salt China" (ASC): Protocol for Campaigns and Randomized Controlled Trials.

Puhong Zhang, Feng J He, Yuan Li, Changning Li, Jing Wu, Jixiang Ma, Bing Zhang, Huijun Wang, Yinghua Li, Junhua Han and 8 more

Open access · goldAbstract read
In one paragraph

Article in JMIR research protocols, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Gastric microbiota dysbiosis andFrontiers in microbiology · 2023
    Review
  17. Article
  18. Article
  19. Article
  20. Latest hypertension research to inform clinical practice in Asia.Hypertension research : official journal of the Japanese Society of Hypertension · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 3 countries.

Puhong Zhang *The George Institute for Global Health at Peking University Health Science Center, Beijing, China.ORCID https://orcid.org/0000-0003-4610-9848
Feng J He *Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom.ORCID https://orcid.org/0000-0003-2807-4119
Yuan LiThe George Institute for Global Health at Peking University Health Science Center, Beijing, China.ORCID https://orcid.org/0000-0003-1887-7065
Changning LiSurveillance Department, Chinese Center for Health Education, Beijing, China.ORCID https://orcid.org/0000-0003-1234-6423
Jing WuThe National Center for Chronic and Noncommunicable Disease Control and Prevention, The Chinese Center for Disease Control and Prevention, Beijing, China.ORCID https://orcid.org/0000-0003-3519-0839
Jixiang MaChronic Diseases and Aging Health Management Division, The Chinese Center for Disease Control and Prevention, Beijing, China.ORCID https://orcid.org/0000-0002-9649-0088
Bing ZhangNational Institute for Nutrition and Health, The Chinese Center for Disease Control and Prevention, Beijing, China.ORCID https://orcid.org/0000-0002-8399-9061
Huijun WangNational Institute for Nutrition and Health, The Chinese Center for Disease Control and Prevention, Beijing, China.ORCID https://orcid.org/0000-0002-8064-4564
Yinghua LiSurveillance Department, Chinese Center for Health Education, Beijing, China.ORCID https://orcid.org/0000-0002-0371-8304
Junhua HanFood Policy, China National Center for Food Safety Risk Assessment, Beijing, China.ORCID https://orcid.org/0000-0002-5224-9292
Rong LuoThe George Institute for Global Health at Peking University Health Science Center, Beijing, China.ORCID https://orcid.org/0000-0003-2725-9939
Jing HeThe George Institute for Global Health at Peking University Health Science Center, Beijing, China.ORCID https://orcid.org/0000-0002-0458-9276
Xian LiThe George Institute for Global Health at Peking University Health Science Center, Beijing, China.ORCID https://orcid.org/0000-0001-5445-4022
Yu LiuSchool of Computing, Beihang University, Beijing, China.ORCID https://orcid.org/0000-0003-1497-3949
Changqiong WangWolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom.ORCID https://orcid.org/0000-0002-2971-4467
Monique TanWolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom.ORCID https://orcid.org/0000-0003-4287-5553
Graham A MacGregorWolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom.ORCID https://orcid.org/0000-0001-9206-4500
Xinhua LiChinese Center for Disease Control and Prevention, Beijing, China.ORCID https://orcid.org/0000-0002-4701-3963
Chinese Center For Disease Control and Prevention · CNQueen Mary University of London · GBPeking University · CNBeihang University · CNChina National Center for Food Safety Risk Assessment · CNNational Center for Chronic and Noncommunicable Disease Control and Prevention · CN

Funding

Department of Health 16/136/77Medical Research Council MR/J015903/1
6 · The paper itself

Abstract

backgroundSalt intake in China is over twice the maximum recommendation of the World Health Organization. Unlike most developed countries where salt intake is mainly derived from prepackaged foods, around 80% of the salt consumed in China is added during cooking.

objectiveAction on Salt China (ASC), initiated in 2017, aims to develop, implement, and evaluate a comprehensive and tailored salt reduction program for national scaling-up.

methodsASC consists of six programs working in synergy to increase salt awareness and to reduce the amount of salt used during cooking at home and in restaurants, as well as in processed foods. Since September 2018, two health campaigns on health education and processed foods have respectively started, in parallel with four open-label cluster randomized controlled trials (RCTs) in six provinces across China: (1) app-based intervention study (AIS), in which a mobile app is used to achieve and sustain salt reduction in school children and their families; (2) home cook-based intervention study (HIS), in which family cooks receive support in using less salt; (3) restaurant-based intervention study (RIS) targeting restaurant consumers, cooks, and managers; and (4) comprehensive intervention study (CIS), which is a real-world implementation and evaluation of all available interventions in the three other RCTs. To explore the barriers, facilitators, and effectiveness of delivering a comprehensive salt reduction intervention, these RCTs will last for 1 year (stage 1), followed by nationwide implementation (stage 2). In AIS, HIS, and CIS, the primary outcome of salt reduction will be evaluated by 24-hour urinary sodium excretion in 6030 participants, including 5436 adults and 594 school children around 8-9 years old. In RIS, the salt content of meals will be measured by laboratory food analysis of the 5 best-selling dishes from 192 restaurants. Secondary outcomes will include process evaluation; changes in knowledge, attitude, and practice on salt intake; and economic evaluation.

resultsAll RCTs have been approved by Queen Mary Research Ethics Committee and the Institutional Review Boards of leading institutes in China. The research started in June 2017 and is expected to be completed around March 2021. The baseline investigations of the four RCTs were completed in May 2019.

conclusionsThe ASC project is progressing smoothly. The intervention packages and tailored components will be promoted for salt reduction in China, and could be adopted by other countries.

trial registrationChinese Clinical Trial Registry. AIS: ChiCTR1800017553; https://tinyurl.com/vdr8rpr. HIS: ChiCTR1800016804; https://tinyurl.com/w8c7x3w. RIS: ChiCTR1800019694; https://tinyurl.com/uqkjgfw. CIS: ChiCTR1800018119; https://tinyurl.com/s3ajldw. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/15933.

Indexed as

24-hour urinary sodiumChinadietaryrandomized controlled trialssalt reductionscaling-upsodium

Identifiers

PMID32271155
PMCPMC7180507
OpenAlexW3000508615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.